Impact of Lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention

American Journal of Cardiology

Volumn 115, Issue 2, 2015, Pages 157-160

  Konishi, Hirokazu ^a   Miyauchi, Katsumi ^a   Kasai, Takatoshi ^a   Tsuboi, Shuta ^a   Ogita, Manabu ^a   Naito, Ryo ^a   Sai, Eiryu ^a   Fukushima, Yoshifumi ^a   Katoh, Yoshiteru ^a   Okai, Iwao ^a   Tamura, Hiroshi ^a   Okazaki, Shinya ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARCINOMA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY ARTERY DISEASE; INCIDENCE; JAPAN; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK FACTOR; TIME;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; LIPOPROTEIN(A); MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84919663221     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.10.015     Document Type: Article

References (26)

1. E. Steyrer, S. Durovic, S. Frank, W. Giessauf, A. Burger, H. Dieplinger, R. Zechner, and G.M. Kostner The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma J Clin Invest 94 1994 2330 2340
2. H. Ikenaga, M. Ishihara, I. Inoue, T. Kawagoe, Y. Shimatani, F. Miura, Y. Nakama, K. Dai, T. Otani, K. Ejiri, N. Oda, M. Nakamura, and T. Miki Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction Circ J 75 2011 2847 2852
3. I. Kardys, R.M. Oemrawsingh, I.P. Kay, G.T. Jones, S.P. McCormick, J. Daemen, R.J. Van Geuns, E. Boersma, R.T. Van Domburg, and P.W. Serruys Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention Clin Cardiol 35 2012 482 489
4. T. Teramoto, J. Sasaki, S. Ishibashi, S. Birou, H. Daida, S. Dohi, G. Egusa, T. Hiro, K. Hirobe, M. Iida, S. Kihara, M. Kinoshita, C. Maruyama, T. Ohta, T. Okamura, S. Yamashita, M. Yokode, and K. Yokote Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 J Atheroscler Thromb 20 2013 603 615
5. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, L.T. Braun, M.A. Creager, B.A. Franklin, R.J. Gibbons, S.M. Grundy, L.F. Hiratzka, D.W. Jones, D.M. Lloyd-Jones, M. Minissian, L. Mosca, E.D. Peterson, R.L. Sacco, J. Spertus, J.H. Stein, and K.A. Taubert AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association J Am Coll Cardiol 58 2011 2432 2446
6. F. Kronenberg, G. Utermann, and H. Dieplinger Lipoprotein(a) in renal disease Am J Kidney Dis 27 1996 1 25
7. A. Abe, and A. Noma Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population Atherosclerosis 96 1992 1 8
8. J. Loscalzo Lipoprotein(a). A unique risk factor for atherothrombotic disease Arteriosclerosis 10 1990 672 679
9. A.M. Scanu Lipoprotein(a). A genetic risk factor for premature coronary heart disease JAMA 267 1992 3326 3329
10. P.R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B.G. Nordestgaard Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study Circulation 117 2008 176 184
11. Y. Matsumoto, H. Daida, Y. Watanabe, S. Sunayama, H. Mokuno, H. Yokoi, and H. Yamaguchi High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease J Atheroscler Thromb 5 1998 47 53
12. P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, J.J. Kastelein, V. Bittner, and J.C. Fruchart HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
13. M. Miller, C.P. Cannon, S.A. Murphy, J. Qin, K.K. Ray, and E. Braunwald Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730
14. J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
15. G. Dangas, J.A. Ambrose, D.J. D'Agate, J.H. Shao, S. Chockalingham, D. Levine, and D.A. Smith Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease Am J Cardiol 83 1999 583 585 A7
16. P. Stubbs, M. Seed, D. Lane, P. Collinson, F. Kendall, and M. Noble Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes Eur Heart J 19 1998 1355 1364
17. M. Hartmann, C. von Birgelen, G.S. Mintz, M.G. Stoel, H. Eggebrecht, H. Wieneke, M. Fahy, T. Neumann, J. van der Palen, H.W. Louwerenburg, P.M. Verhorst, and R. Erbel Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries J Am Coll Cardiol 48 2006 446 452
18. M. Greif, T. Arnoldt, F. von Ziegler, J. Ruemmler, C. Becker, R. Wakili, M. D'Anastasi, J. Schenzle, A.W. Leber, and A. Becker Lipoprotein (a) is independently correlated with coronary artery calcification Eur J Intern Med 24 2013 75 79
19. V.M. Maher, and B.G. Brown Lipoprotein (a) and coronary heart disease Curr Opin Lipidol 6 1995 229 235
20. D.J. Grainger, H.L. Kirschenlohr, J.C. Metcalfe, P.L. Weissberg, D.P. Wade, and R.M. Lawn Proliferation of human smooth muscle cells promoted by lipoprotein(a) Science 260 1993 1655 1658
21. J. Loscalzo, M. Weinfeld, G.M. Fless, and A.M. Scanu Lipoprotein(a), fibrin binding, and plasminogen activation Arteriosclerosis 10 1990 240 245
22. M. Seed, K.L. Ayres, S.E. Humphries, and G.J. Miller Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men Am J Med 110 2001 22 27
23. M. Seed, B. O'Connor, N. Perombelon, M. O'Donnell, D. Reaveley, and B.L. Knight The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover Atherosclerosis 101 1993 61 68
24. J.J. Albers, A. Slee, K.D. O'Brien, J.G. Robinson, M.L. Kashyap, P.O. Kwiterovich Jr., P. Xu, and S.M. Marcovina Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1575 1579
25. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf, J. Zafarino, Y. Mitchel, and P. Barter Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
26. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353